Loading organizations...
§ Private Profile · Hangzhou, Zhejiang, China
CDMO developing and manufacturing antibody and recombinant protein biologics for global biopharmaceutical partners.
Hangzhou Just Biotherapeutics (Just China) develops and manufactures antibody and recombinant protein biologics, operating primarily from Hangzhou, China. The company utilizes advanced platforms like J.DESIGN to offer contract development and manufacturing organization (CDMO) services, aiming for global quality standards with cost and speed efficiencies. By 2018, Just China had raised over $120 million in total financing, including a $35 million Series B+ round in June 2018. Key investors in these rounds included Temasek, Lilly Asia Ventures (LAV), ARCH Venture Partners, and Hillhouse Capital. Its operations span R&D and manufacturing in Hangzhou, alongside a clinical development center established in Boston, focusing on biologics for orphan diseases, cancer, and immunology. Founded in February 2016, the organization was co-founded by Yining Zhao and Jonathan Zhao.
Hangzhou Just Biotherapeutics (Just China) has raised $35.0M across 1 funding round.
Hangzhou Just Biotherapeutics (Just China) has raised $35.0M in total across 1 funding round.
Hangzhou Just Biotherapeutics (Just China) has raised $35.0M across 1 funding round. Most recently, it raised $35.0M Series B in June 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 6, 2018 | $35M Series B | Hillhouse Capital | ARCH Venture Partners, Lilly Asia Ventures, Taikang, Temasek | Announced |
Hangzhou Just Biotherapeutics (Just China) has raised $35.0M in total across 1 funding round.
Hangzhou Just Biotherapeutics (Just China)'s investors include Hillhouse Capital, ARCH Venture Partners, Lilly Asia Ventures, Taikang, Temasek.